The Commercial Market For Priority Review Vouchers.

@article{Ridley2016TheCM,
  title={The Commercial Market For Priority Review Vouchers.},
  author={David B. Ridley and Stephane A. Regnier},
  journal={Health affairs},
  year={2016},
  volume={35 5},
  pages={
          776-83
        }
}
In 2007 the US Congress created the priority review voucher program to encourage the development of drugs for neglected diseases. Under the program, the developer of a drug that treats a neglected disease receives both a faster review of the drug by the Food and Drug Administration and a voucher for a faster review of a different drug. The developer can sell the voucher. We estimated the commercial value of the voucher using US sales of new treatments approved in the period 2007-09. A third of… 

Topics from this paper

Priorities for the Priority Review Voucher
  • D. Ridley
  • Medicine
    The American journal of tropical medicine and hygiene
  • 2017
TLDR
The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases and recent experience indicates strengths and weaknesses of the program, as well as a need for legislative changes.
Expansion of the Priority Review Voucher Program Under the 21st Century Cures Act: Implications for Innovation and Public Health
The U.S. federal government awards a priority review voucher (“PRV”) to a pharmaceutical manufacturer after the Food and Drug Administration (“FDA”) approves a product for one of a list of
Suitability of expanding the priority review voucher into rare disease drug development
TLDR
There are fundamental shortcomings with the PRV mechanism that make it a poor fit for this purpose, and strong evidence from real-world experience that the program is working as intended should be required before considering further expansion.
Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.
TLDR
Compared to drugs for rare adult diseases, drugs forRare pediatric diseases progressed more quickly through all phases of clinical testing and were more likely to be first-in-class.
Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years
TLDR
Here it is shown how the prospect of the PRV facilitated FDA approval of a new treatment for onchocerciasis, a milestone towards its availability to affected populations that otherwise might not have been achieved.
Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives
  • Emily Harris
  • Medicine, Business
    Journal of law and the biosciences
  • 2018
TLDR
It is uncertain whether a Canadian orphan drug policy, similar to those used in the US and EU, will be given further consideration, but an orphan drug-specific tax credit offering a convenient means of subsidizing orphan drug development without being overly costly is recommended.
Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
TLDR
A fertile ground for high-priced drugs has been created by changes in drug life-cycle dynamics, the unintended effects of patent legislation, government policy measures and orphan drug programs.
Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997
TLDR
It is shown that the limited duration of exclusivity reduces the number of secondary indications significantly, and the imminence of generic entry still has a detectable impact on reducing the chances of new indication additions.
Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
TLDR
Alternative pricing strategies for coronavirus disease 2019 (COVID-19) drugs, vaccines, and diagnostics are reviewed and the added value of social benefits into cost effectiveness analyses is incorporated.
Increases in Thyroid Cancer Incidence and Mortality.
TLDR
An improved incentive scheme would reduce the risk of neglected tropical disease product development such as by decreasing the cost of clinical trials to pharmaceutical companies and a publicprivate partnership could provide financial support to sponsors of neglected Tropical disease products.
...
1
2
3
...

References

SHOWING 1-10 OF 24 REFERENCES
Experience With the Priority Review Voucher Program for Drug Development.
TLDR
Federal legislation offering priority review vouchers to companies that sponsored drugs newly approved by the US Food and Drug Administration to treat qualifying neglected tropical diseases, including tuberculosis, malaria, schistosomiasis, and yaws, and three pediatric disease PRVs have been awarded since 2012.
Priority Review Vouchers: An Inefficient and Dangerous Way to Promote Neglected‐Disease Drug Development
  • A. Kesselheim
  • Business, Medicine
    Clinical pharmacology and therapeutics
  • 2009
TLDR
The voucher program for development of drugs aimed at neglected diseases is likely to be bad policy because they are cost-ineffective and potentially dangerous, and the effort to engage for-profit companies in neglected-disease research will lead to wasteful spending with no guarantee of results.
The Impact of the US Priority Review Voucher on Private-Sector Investment in Global Health Research and Development
TLDR
The priority review voucher (PRV) program, currently administered by the US Food and Drug Administration, was passed into United States law in 2007 as a pull mechanism to help promote R&D for new medicines targeting NTDs, malaria, and tuberculosis.
Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases
TLDR
A priority review voucher scheme, as is already in place in the USA, would reward a manufacturer that developed a new medicine for neglected diseases with a voucher that could be redeemed for priority review of a future medicine, probably a potential blockbuster drug.
In Defence of Priority Review Vouchers
TLDR
It is argued that with a few amendments in place, the priority review voucher scheme constitutes an attractive way of stimulating R&D of drugs for neglected diseases.
Analysis of Neglected Tropical Disease Drug and Vaccine Development Pipelines to Predict Issuance of FDA Priority Review Vouchers over the Next Decade
TLDR
An analysis of the drug and vaccine development pipeline is presented to identify products that meet eligibility criteria to earn a priority review voucher (PRV), and predict the number of PRVs that will be issued over the next 10 years.
Innovation in the pharmaceutical industry: New estimates of R&D costs.
The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug and
Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
TLDR
A commitment comparable in value to sales earned by the average of a sample of recently launched commercial products (adjusted for lower marketing costs) would be a highly cost-effective way to address HIV/AIDS, malaria, and tuberculosis.
Market watch: Forecasting market share in the US pharmaceutical market
TLDR
This study is unique in combining a large sample of drug classes with data on entry order and promotional spending to estimate peak market share while controlling for product quality.
The roles of patents and research and development incentives in biopharmaceutical innovation.
TLDR
It is concluded that patents and regulatory exclusivity provisions are likely to remain the core approach to providing incentives for biopharmaceutical research and development, and prizes and other voluntary supplements could play a useful role in addressing unmet needs and gaps in specific circumstances.
...
1
2
3
...